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Abstract: MOMAST(®) HY100 and MOMAST(®) HP30 are polyphenolic liquid complexes from olive
pressing juice with a total polyphenolic content of 100 g/kg (at least 50% as hydroxytyrosol) and
36 g/kg (at least 30% as hydroxytyrosol), respectively. We investigated the potential protective role
of MOMAST(®) HY100 and MOMAST(®) HP30 on isolated rat colon, liver, heart, and prefrontal
cortex specimens treated with Escherichia coli lipopolysaccharide (LPS), a validated ex vivo model
of inflammation, by measuring the production of prostaglandin (PG)E2, 8-iso-PGF2α, lactate
dehydrogenase (LDH), as well as cyclooxygenase (COX)-2, tumor necrosis factor α (TNFα),
and inducible nitric oxide synthase (iNOS) mRNA levels. MOMAST(®) HY100 decreased
LPS-stimulated PGE2 and LDH levels in all tested tissues. Following treatment with MOMAST(®)
HY100, we found a significant reduction in iNOS levels in prefrontal cortex and heart specimens,
COX-2 and TNFα mRNA levels in heart specimens, and 8-iso-PGF2α levels in liver specimens. On the
other hand, MOMAST(®) HP30 was found to blunt COX-2, TNFα, and iNOS mRNA levels, as well as
8-iso-PGF2α in cortex, liver, and colon specimens. MOMAST(®) HP30 was also found to decrease
PGE2 levels in liver specimens, while it decreased iNOS mRNA, LDH, and 8-iso-PGF2α levels in
heart specimens. Both MOMAST(®) HY100 and MOMAST(®) HP30 exhibited protective effects on
multiple inflammatory and oxidative stress pathways.
Keywords: Cultivar Coratina; inflammation; oxidative stress; hydroxytyrosol
1. Introduction
It has been well established that olive tree (Olea europaea) polyphenols have healthy beneficial effects,
including the prevention of several chronic diseases, such as cancer and aging-associated degenerative
diseases [1,2]. These beneficial properties could be mainly related to the antioxidant activity of
olive tree polyphenols, which were found able to both scavenge free radicals and reactive oxygen
species and activate endogenous antioxidant enzymes, including glutathione peroxidase, glutathione
reductase, and glutathione S-transferase [3–5]. Besides the antioxidant activity, anti-atherogenic,
hepato-protective, hypoglycemic, anti-inflammatory, immunomodulatory, anticancer, and antimicrobic
effects were also suggested for these compounds [5–7]. Hydroxytyrosol (HT) and the secoiridoid
oleuropein (OE) are two abundant phenolic compounds in olives, virgin oil, and waste water from
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olive oil production [8–10]. Particularly, HT has antioxidant and scavenging activities comparable to
oleuropein and catechol [11].
MOMAST(®) HY100 and MOMAST(®) HP30 (Bioenutra, Ginosa, TA, Italy) are polyphenolic liquid
complexes from olive (Olea europaea, mainly Cultivar Coratina) pressing juice with a total polyphenolic
content of 100 g/kg (at least 50% as HT) and 36 g/kg (at least 30% as HT), respectively (Tables 1 and 2).
In addition to HT, both MOMAST(®) HY100 and MOMAST(®) HP30 are also characterized by the
presence of tyrosol and oleuropein.
Table 1. Characteristics of the polyphenolic complex MOMAST(®) HY 100.
Name: MOMAST HY 100
Description: Polyphenolic active complex of hydroxytyrosol—Liquid, with totalpolyphenolic content of 100 g/kg
Source Type: Mainly Cultivar Coratina
Physical State: Liquid
Appearance: Light brown to brown liquid
Moisture: N.A.
Ash: Less than 10% (600 ◦C)
Total heavy (as Pb): Less than 10 ppm
Total Plate Count: Less than 100 cfu/g
Pesticides: Absence
Polyphenolic content measured through high performance liquid chromatography (HPLC)
Hydroxytyrosol (HPLC): 50 g/Kg
Tyrosol (HPLC) 15 g/kg
Oleuropein (HPLC) 0.5 g/Kg
Total Polyphenols (HPLC) 100 g/Kg
Table 2. Characteristics of the Polyphenolic Complex MOMAST(®) HP 30.
Name: MOMAST HP 30
Description: Polyphenolic active complex from olives’ pressing juice—Liquid, with totalpolyphenolic content of 30 g/kg
Source Type: Mainly Cultivar Coratina
Fisic State: Liquid
Appearance: Brown liquid
Moisture: N. A.
Ash: Less than 10% (600 ◦C)
Total heavy (as Pb): Less than 10 ppm
Total Plate Count: Less than 100 cfu/g
Pesticides: Absence
Polyphenolic Content
Hydroxytyrosol (HPLC): 15 g/Kg
Tyrosol (HPLC) 3 g/kg
Oleuropein (HPLC) 0.2 g/Kg
Total Polyphenols (HPLC) 30 g/Kg
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Considering the antioxidant effects displayed by both HT and oleuropein, the aim of the present
study was to investigate the putative protective effects of MOMAST(®) HY100 and MOMAST(®) HP30,
both including HT and oleuropein, on the burden of oxidative stress/inflammation occurring on various
isolated rat tissue (i.e., colon, liver, heart, and prefrontal cortex) specimens exposed to Escherichia
coli lipopolysaccharide (LPS), a well-established inflammatory stimulus. Specifically, we studied the
effects of MOMAST(®) HY100 and MOMAST(®) HP30 on multiple inflammatory and oxidative stress
pathways, by measuring the production of prostaglandin (PG)E2, 8-iso-PGF2α, lactate dehydrogenase
(LDH), as well as cyclooxygenase (COX)-2, tumor necrosis factor α (TNFα), and inducible nitric oxide
synthase (iNOS) mRNA levels. The results support a rational use of these polyphenolic complexes in
the prevention of tissue damage occurring during inflammation.
2. Results and Discussion
MOMAST(®) HY100 (10, 50, and 100 µg/mL) and MOMAST(®) HP30 (22, 110, and 220 µg/mL)
were tested in vitro to evaluate their effects on cell viability. We observed that both polyphenolic liquid
complexes were well tolerated by Hypo-E22 and C2C12 cell lines (Supplementary Figures S1–S2).
Particularly, C2C12 and Hypo-E22 cell viability resulted in the limit of biocompatibility (>70 and <130%
compared to the untreated control group) after exposition to polyphenolic extracts, in the respective
tested concentration range, corresponding to identical concentrations of HT (5–50 µg/mL), which were
in agreement with previous in vitro studies [11].
Considering these findings, we performed a second set of experiments aimed to evaluate the
modulatory effects of MOMAST(®) HY100 (10, 50, and 100 µg/mL) and MOMAST(®) HP30 (22, 110,
and 220 µg/mL) supplementation on oxidative stress and multiple inflammatory pathways in colon,
liver, heart, and prefrontal cortex specimens challenged with LPS. As previously reported [12–14],
isolated tissues challenged with LPS is a validated ex vivo experimental model to evaluate the
modulatory effects of herbal extracts and drugs on inflammatory pathways and oxidative stress.
The beneficial effects of plant polyphenols in humans have been confirmed by a large body of
evidence [15–18]. A number of studies confirmed the antioxidant, anti-atherogenic, and protective
effects of olive polyphenols, such as OLE and HT, against coronary artery disease [19–23]. In particular,
HT, deacetoxy oleuropein aglycon, and oleuropein aglycon were classified as the strongest antioxidants
in virgin olive oils [24]. Oxidative stress is defined as an imbalance in the pro-oxidant/antioxidant
homeostasis, where increased production of reactive oxygen/nitrogen species (ROS/RNS) and free
radicals can induce peroxidation reactions on biomolecules including proteins, lipids, and nucleic
acids [25,26]. Oxidative damage is thought to play a key role in the pathogenesis of various
chronic diseases, including cancer, atherosclerosis, cardiovascular diseases, chronic inflammation,
and diabetes [27–29]. 8-Iso-PGF2α, an isomer of prostaglandins produced by free radical-catalyzed
peroxidation of membrane arachidonic acid, is a stable marker of lipid peroxidation and oxidative
stress [30]. We found that MOMAST(®) HP30 (110 and 220 µg/mL) was able to decrease 8-iso-PGF2α
levels on rat prefrontal cortex, colon, liver, and heart tissues, challenged with LPS inflammatory
stimulus (Figures 1–4).
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lipopolysaccharide (LPS)-treated group. 
 
Figure 2. Effects of MOMAST(®) HY100 (10, 50, and 100 µg/mL) and MOMAST(®) HP30 (22, 110, and 
220 µg/mL) on (A) PGE2 levels (pg/mg wet tissue), (B) 8-iso-prostaglandin F2α (8-iso-PGF2α) levels, 
and (C) lactate dehydrogenase (LDH) activity (nmol/L) in colon specimens. Data were reported as 
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and (C) lactate dehydrogenase (LDH) activity (nmol/L) in rat liver specimens. Data were reported as
means ± SEM. ANOVA, p < 0.01; post-hoc test, * p < 0.05, ** p < 0.01, *** p < 0.001 vs. LPS-treated group.
Molecules 2019, 24, x 5 of 14 
 
 
Figure 3. Effects of OMAST(®) HY100 (10, 50, and 100 µg/mL) and MOMAST(®)  , , and 
 / ) on (A) PGE2 levels (pg/mg wet tissue), (B) 8-is -prostaglandin F2α (8-iso-PGF2α) evels, 
and (C) lactate dehydrog nase (LDH) activity (nmol/L) in rat liv r sp cimens. Data w re eported as 
means ± SEM. ANOVA, p < 0.01; p st-hoc test, * p < 0.05, ** p < 0.01, *** p < 0.001 vs. LPS-treated group. 
 
Figure 4. Effects of MOMAST(®) HY100 (10, 50, and 100 µg/mL) and MOMAST(®) HP30 (22, 110, and 
220 µg/mL) on (A) PGE2 levels (pg/mg wet tissue), (B) 8-iso-prostaglandin F2α (8-iso-PGF2α) levels, 
and (C) lactate dehydrogenase (LDH) activity (nmol/L) in rat heart specimens. Data were reported as 
means ± SEM. ANOVA, p < 0.01; post-hoc test, * p < 0.05, ** p < 0.01, *** p < 0.001 vs. LPS-treated group. 
Figure 4. Effects of MOMAST(®) HY100 (10, 50, and 100 µg/mL) and MOMAST(®) HP30 (22, 110,
and 220 µg/mL) on (A) PGE2 levels (pg/mg wet tissue), (B) 8-iso-prostaglandin F2α (8-iso-PGF2α) levels,
and (C) lactate dehydrogenase (LDH) activity (nmol/L) in rat heart specimens. Data were reported as
means ± SEM. ANOVA, p < 0.01; post-hoc test, * p < 0.05, ** p < 0.01, *** p < 0.001 vs. LPS-treated group.
Molecules 2019, 24, 3002 6 of 14
Moreover, MOMAST(®) HY100 (10, 50, and 100 µg/mL) was effective in inhibiting LPS-induced
8-iso-PGF2α in rat liver specimens (Figure 3B). These effects could be related, at least in part, to the free
radical-reducing and -scavenging properties of HT [31,32], which is found in very high amounts in
MOMAST(®) HY100 and MOMAST(®) HP30 (at least 50% and 30% of the phenolic fraction, respectively).
HT was also shown to decrease low density lipoproteins oxidation [33], platelet aggregation [34],
and 5- and 12-lipoxygenase activity [35] in vitro. However, we cannot exclude that our findings could
also be related to other phenolic compounds which are present, even if in low content, in both liquid
complexes. In this context, the antioxidant activity of OE has been widely confirmed both in vitro
and in vivo [36]. We also investigated the activity of MOMAST(®) HY100 and MOMAST(®) HP30
on LDH level in inflamed tissues. LDH is a cytosolic enzyme, which can be considered a marker of
tissue destruction [37,38]. Additionally, decreased LDH activity after treatment with herbal extracts
has been related to protective effects in chronic inflammatory disorders such as inflammatory bowel
disease (IBD) [39]. Following MOMAST(®) HY100 (10, 50, and 100 µg/mL) treatment, we found
a significant inhibition of LPS-induced LDH level in all tested tissues (Figures 1–4). MOMAST(®)
HP30 (22, 110, and 220 µg/mL) was also able to decrease LDH level induced by LPS in heart specimens
(Figure 7C). Actually, the reduction of LDH level could be related to the presence of HT [40] in both
extracts, and further supports the protective effects induced by MOMAST(®) HY100 and MOMAST(®)
HP30. Finally, we evaluated the modulatory effects of MOMAST(®) HY100 and MOMAST(®) HP30
on pro-inflammatory markers, including PGE2, COX-2, TNFα, and iNOS. LPS was found to induce
macrophage production of inflammatory cytokines such as TNFα, interleukin-1β (IL-1β), and IL-6,
along with inflammatory mediators including nitric oxide (NO) and PGE2 [41,42]. COX-2, an inducible
enzyme stimulated by mitogenic and inflammatory stimuli, including LPS and cytokines, is known
to be mainly involved in the synthesis of pro-inflammatory PGE2 in both neoplastic and inflamed
tissues [43]. Similarly, iNOS, whose expression is induced by exposure to a number of stimuli, including
LPS and TNFα, is involved in the generation of large amounts of NO, which plays a pivotal role in
acute and chronic inflammation [44–46]. Following LPS inflammatory stimulus, we observed that
MOMAST(®) HP30 was able to reduce COX-2, TNFα, and iNOS mRNA levels in prefrontal cortex,
colon, and liver specimens (Figures 5–7).
Molecules 2019, 24, x 6 of 14 
 
 
Figure 5. Effects of MOMAST(®) HY100 (10, 50, and 100 µg/mL) and MOMAST(®) HP30 (22, 110, and 
220 µg/mL) on (A) cyclooxygenase (COX)-2, (B) tumor necrosis factor α (TNFα), and (C) inducible 
nitric oxide synthase (iNOS) in rat prefrontal cortex specimens. Data were reported as means ± SEM. 
ANOVA, p < 0.01; post-hoc test, * p < 0.05, ** p < 0.01, *** p < 0.001 vs. LPS-treated group. 
 
Figure 6. Effects of MOMAST(®) HY100 (10, 50, and 100 µg/mL) and MOMAST(®) HP30 (22, 110, and 
220 µg/mL) on (A) cyclooxygenase (COX)-2, (B) tumor necrosis factor α (TNFα), and (C) inducible 
nitric oxide synthase (iNOS) in rat colon specimens. Data were reported as means ± SEM. ANOVA, p 
< 0.01; post-hoc test, * p < 0.05, ** p < 0.01, *** p < 0.001 vs. LPS-treated group. 
Figure 5. Effects of MOMAST(®) HY100 (10, 50, and 100 µg/mL) and MOMAST(®) HP30 (22, 110,
and 220 µg/mL) on (A) cyclooxygenase (COX)-2, (B) tumor necrosis factor α (TNFα), and (C) inducible
nitric oxide synthase (iNOS) in rat prefrontal cortex specimens. Data were reported as means ± SEM.
ANOVA, p < 0.01; post-hoc test, * p < 0.05, ** p < 0.01, *** p < 0.001 vs. LPS-treated group.
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On the other hand, COX-2, TNFα, and iNOS mRNA levels were decreased by MOMAST(®)
HY100 in heart tissue specimens (Figure 8). iNOS mRNA levels were also decreased by MOMAST(®)
HY100 in prefrontal cortex specimens (Figure 5C) and by MOMAST(®) HP30 in heart tissue specimens
(Figure 8C).
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As regards PGE2, we found that while MO AST(®) HY100 was effective in reducing LPS-induced
PGE2 levels in all tested tissues (Figures 1–4), MOMAST(®) HP30 was able to decrease PGE2 levels only
in liver tissue (Figure 5A). The inhibitory effects induced by MOMAST(®) HY100 and MOMAST(®)
HP30 on PGE2 levels, along with COX-2, TNFα, and iNOS mRNAs, support the protective effects of
both polyphenolic liquid complexes in prefrontal cortex, colon, liver, and heart specimens. Accordingly,
HT was shown to exert anti-inflammatory effects in LPS-stimulated RAW264.7 mouse macrophages by
suppressing nuclear factor-kB (NF-κB) signaling and downregulating gene expression of iNOS, COX-2,
TNFα, and IL-1β, and production of NO and PGE2 [47]. We hypothesize that the protective effects
induced by MOMAST(®) HY100 and MOMAST(®) HP30 could also be related to the presence of other
phenolic compounds, including tyrosol and OE. In this context, tyrosol was found to significantly
inhibit COX-2 gene and protein expression, as well as PGE2 secretion in human glioblastoma cells [48].
Moreover, it has been found that OE significantly downregulated NO, COX-2, iN S, and TNF-α
in RAW264.7 macrophages following LPS treatment [49]. However, our findings indicate that
MOMAST(®) HY100 and MOMAST(®) HP30 could display different effects in tissues. On one hand,
Takeda et al. [50] reported that HT was able to suppress iNOS expression and NO production without
any effect on NF-kB, COX-2, and TNFα expression in mouse peritoneal macrophages challenged with
LPS; on the other hand, Maiuri et al. [51] and Zhang et al. [52] showed that HT was able to inhibit
LPS-stimulated NFκB activation as well as COX-2 gene expression, in J774 murine macrophages and
human monocytic THP-1 cells, respectively.
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In conclusion, both MOMAST(®) HY100 and MOMAST(®) HP30 exhibited protective effects as
indicated by the blunting effect on the tested pro-inflammatory mediators. On the basis of these results,
HT seems to be the main extract component involved in the pharmacological effects. Nevertheless,
considering the inherent limitations of the ex vivo experimental model, further investigations including
oxidative stress and inflammation biomarkers in in vivo studies are needed for a more accurate
evaluation of MOMAST(®) HY100 and MOMAST(®) HP30 efficacy.
3. Materials and Methods
3.1. In Vitro Studies
Rat Hypo-E22 cells (Cedarlane Cellution Biosystem) and mouse myoblast C2C12 cell lines (ATCC®
CRL-1772™) were cultured in Dulbecco’s modified eagle medium (DMEM) supplemented with 10% (v/v)
heat-inactivated fetal bovine serum and 1.2% (v/v) penicillin G/streptomycin in 75 cm2 tissue culture flask
(n = 5 individual culture flasks for each condition). The cultured cells were maintained in a humidified
incubator with 5% CO2 at 37 ◦C. For cell differentiation, Hypo-E22 and C2C12 cell suspensions at
a density of 1 × 106 cells/mL were treated with various concentrations (10, 50, and 100 ng/mL) of
phorbol myristate acetate (PMA, Fluka) for 24 h or 48 h (induction phase). Thereafter, the PMA-treated
cells were washed twice with ice-cold pH 7.4 phosphate buffer solution (PBS) to remove PMA and
non-adherent cells, whereas the adherent cells were further maintained for 48 h (recovery phase).
The morphology of the cells was examined under an inverted phase-contrast microscope. To assess the
basal cytotoxicity of MOMAST(®) HY100 and MOMAST(®) HP30, a viability test was performed on
96-microwell plates, using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test.
Cells were incubated with MOMAST(®) HY100 (10, 50, and 100 µg/mL) and MOMAST(®) HP30 (22,
110, and 220 µg/mL), corresponding to HT (5, 25, and 50 µg/mL, respectively), for 24 h. Ten microliters
of MTT (5 mg/mL) were added to each well and incubated for 3 h. The formazan dye formed was
extracted with dimethyl sulfoxide and the absorbance was recorded as previously described [12,52].
The effects on cell viability were evaluated in comparison to the untreated control group.
3.2. Ex Vivo Studies
Male adult Sprague-Dawley rats (200–250 g) were housed in Plexiglass cages
(40 cm × 25 cm × 15 cm), two rats per cage, in climatized colony rooms (22 ± 1 ◦C; 60% humidity),
on a 12 h/12 h light/dark cycle (light phase: 07:00–19:00 h), with free access to tap water and food,
24 h/day throughout the study, with no fasting periods. Rats were fed a standard laboratory diet (3.5%
fat, 63% carbohydrate, 14% protein, 19.5% other components without caloric value; 3.20 kcal/g).
Housing conditions and experimentation procedures were strictly in accordance with the European
Union ethical regulations on the care of animals for scientific research.
According to the recognized ethical principles of “Replacement, Refinement, and Reduction of
Animals in Research”, colon, liver, heart, and prefrontal cortex specimens were obtained as residual
material from vehicle-treated rats randomized in our previous experiments approved by the Local
Ethical Committee of University “G. d’Annunzio” and the Italian Health Ministry (Italian Health
Ministry authorization N. 880, delivered on 24th August 2015). Rats were sacrificed by CO2 inhalation
(100% CO2 at a flow rate of 20% of the chamber volume per min) and colon, liver, heart, and prefrontal
cortex specimens were immediately collected and maintained in a humidified incubator with 5% CO2
at 37 ◦C for 4 h, in DMEM buffer with added bacterial LPS (10 µg/mL) (incubation period).
During the incubation period, tissues were treated with scalar concentrations of MOMAST(®)
HY100 (10, 50, and 100 µg/mL) and MOMAST(®) HP30 (22, 110, and 220 µg/mL). Tissue supernatants
were collected, and the PGE2 and 8-iso-PGF2α levels (ng/mg wet tissue) were measured by
radioimmunoassay (RIA), as previously reported [13,53]. Briefly, specific anti-8-iso-PGF2α and
anti-PGE2 were developed in the rabbit; the cross-reactivity against other prostanoids is <0.3%.
One hundred microliters of prostaglandin standard or sample were incubated overnight at 4 ◦C with
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the 3H-prostaglandin (3000 cpm/tube; NEN) and antibody (final dilution: 1:120,000; kindly provided
by Prof. G. Ciabattoni), in a volume of 1.5 mL of 0.025 M phosphate buffer. Free and antibody-bound
prostaglandins were separated by the addition of 100 µL 5% bovine serum albumin and 100 µL 3%
charcoal suspension, followed by centrifuging for 10 min at 4,000× g at 5 ◦C and decanting off the
supernatants into scintillation fluid (Ultima Gold™, Perkin Elmer, Waltham, MA, USA) for β emission
counting. The detection limit of the assay method was 0.6 pg/mL. Additionally, tissue supernatants
were assayed for lactate dehydrogenase (LDH) activity [54]. LDH activity was measured by evaluating
the consumption of nicotinamide adenine dinucleotide dehydrogenase (NADH) in 20 mM HEPES-K+
(pH 7.2), 0.05% bovine serum albumin, 20 µM NADH, and 2mM pyruvate using a microplate reader
(excitation 340 nm, emission 460 nm) according to manufacturer′s protocol (Sigma-Aldrich, St. Louis,
MO). LDH activity was measured by evaluating the consumption of NADH in 20 mM HEPES-K+
(pH 7.2), 0.05% bovine serum albumin, 20 µM NADH and 2 mM pyruvate using a microplate reader
(excitation 340 nm, emission 460 nm) according to manufacturer′s protocol. In addition, individual
prefrontal cortex, colon, liver, and heart specimens were quickly dissected to evaluate cyclooxygenase
(COX)-2, tumor necrosis factor α (TNFα), and inducible nitric oxide synthase (iNOS) gene expression,
as previously reported [55,56]. Tissue specimens were dissected and stored in RNAlater solution
(Life Technologies, Carlsbad, CA, USA) at −20 ◦C until further processed. Total RNA was extracted
from the tissues using TRI Reagent (Sigma-Aldrich, St. Louis, MO, USA) according to manufacturer’s
protocol. One microgram of total RNA extracted from each sample in a 20-µL reaction volume
was reverse transcribed using a high capacity cDNA reverse transcription kit (Life Technologies,
Carlsbad, CA, USA). Reactions were incubated in a 2720 thermal cycler (Life Technologies, Carlsbad,
CA, USA) initially at 25 ◦C for 10 min, then at 37 ◦C for 120 min, and finally at 85 ◦C for 5 s.
Gene expression was determined by quantitative real-time PCR using TaqMan probe-based chemistry
(Life Technologies, Carlsbad, CA, USA). Reactions were performed in MicroAmp Fast Optic 96-well
Reaction Plates (Life Technologies, Carlsbad, CA, USA) on an ABI PRISM 7900 HT fast real-time PCR
system (Life Technologies, Carlsbad, CA, USA). PCR primers and TaqMan probes were obtained
from Life Technologies (Assays-on-Demand Gene Expression Products, Rn01483828_m1 for COX-2
gene, Rn01525859_g1 for TNFα, Rn00561646_m1 for iNOS. β-actin (Life Technologies, Carlsbad, CA,
USA, Part No. 4352340E) was used as the housekeeping gene. The real-time PCR was carried out
in triplicate. Data were elaborated with the sequence detection system (SDS) software version 2.3
(Applied Biosystems, Foster City, CA, USA). The comparative 2−∆∆Ct method was used to quantify the
relative abundance of mRNA and then determine the relative changes in individual gene expression
(relative quantification) [57].
3.3. Statistical Analysis
Statistical analysis was performed using GraphPad Prism version 5.01 for Windows (GraphPad
Software, San Diego, CA, USA). Means ± S.E.M. were determined for each experimental group and
analyzed by one-way analysis of variance (ANOVA), followed by Newman–Keuls comparison multiple
test. As for gene expression analysis, 1.00 (calibrator sample) was considered the theoretical mean for
the comparison [57]. Statistical significance was set at p < 0.05. The number of animals randomized
for each experimental group was calculated on the basis of the “Resource Equation” N = (E + T)/T
(10 ≤ E ≤ 20) [58–60], according to the guidelines suggested by the National Centre for the Replacement,
Refinement, and Reduction of Animals in Research (NC3RS) and reported on the following web site:
https://www.nc3rs.org.uk/experimental-designstatistics.
Supplementary Materials: The following are available on line: Supplementary Figure S1: Effects of MOMAST(®)
HY100 (10, 50, and 100 µg/mL) and MOMAST(®) HP30 (22, 110, and 220 µg/mL) on HypoE22 cell line viability.
Supplementary Figure S2: Effects of MOMAST(®) HY100 (10, 50, and 100 µg/mL) and MOMAST(®) HP30 (22, 110,
and 220 µg/mL) on C2C12 cell line viability.
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